Preliminary evaluation of oligomannose-coated liposome vaccines against lethal protozoan infections in mice

DOI IR
  • Kuboki Noritaka
    National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan
  • Tiwananthagorn Weerawan
    National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan
  • Takagi Hideaki
    The Institute of Glycotechnology and the Department of Applied Biochemistry, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan
  • Nakayama Tomoko
    The Institute of Glycotechnology and the Department of Applied Biochemistry, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan
  • Xuan Xuenan
    National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan
  • Inoue Noboru
    National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan
  • Igarashi Ikuo
    National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan
  • Tsujimura Kunio
    Division of Immunology, Aichi, Cancer Center Research Institute, Nagoya, Aichi 464-8681, Japan
  • Ikehara Yuzuru
    Research Center for Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 205-8568, Japan
  • Kojima Naoya
    The Institute of Glycotechnology and the Department of Applied Biochemistry, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan
  • Yokoyama Naoaki
    National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan

Search this article

Abstract

The oligomannose-coated liposome (OML) vaccine is known to induce cellular immunity specific for the encapsulated antigen in immunized mice. In the present study, we preliminarily evaluated the effect of the OML vaccine encapsulating the soluble protozoan lysate of Toxoplasma gondii, Trypanosoma brucei gambiense, or Babesia rodhaini on the corresponding protozoan infections in mice. After the challenge of T. gondii, the OML vaccine group avoided the high mortality resulting from acute infection that was dominantly observed in other control groups. During the infectious course, the development of the T. gondii-specific antibody, which is an indicator of humoral immunity, was constantly controlled at a lower level in the surviving mice of the OML vaccine group than in other lethally affected mice. On the other hand, other OML vaccines targeting for T. b. gambiense and B. rodhaini did not show any effect on these lethal infections in mice. The present preliminary study suggests that OML is a novel vaccine tool, at least for the control of acute toxoplasmosis.

Journal

  • The Journal of Protozoology Research

    The Journal of Protozoology Research 17 (1), 9-15, 2007

    National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine

Keywords

Details 詳細情報について

Report a problem

Back to top